Welcome to our dedicated page for Vanda Pharma SEC filings (Ticker: VNDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vanda Pharmaceuticals Inc. (VNDA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Vanda describes its commercial portfolio, clinical pipeline, financial condition, and interactions with the U.S. Food and Drug Administration.
Recent Form 8-K filings referenced by Vanda include earnings announcements and disclosures about a collaborative framework with the FDA regarding HETLIOZ (tasimelteon) and tradipitant. Through these current reports, investors can review management’s discussion of net product sales for Fanapt, HETLIOZ, and PONVORY, as well as updates on NDAs and BLAs for programs such as Bysanti, tradipitant in motion sickness, and imsidolimab in generalized pustular psoriasis.
On Stock Titan, VNDA filings are updated in near real time from EDGAR and paired with AI-powered summaries that explain the key points of lengthy documents. For annual reports on Form 10-K and quarterly reports on Form 10-Q, AI highlights sections related to Vanda’s commercial products, research and development spending, and risk factors tied to regulatory decisions and clinical trial outcomes. For current reports on Form 8-K, AI summaries focus on the specific material events being disclosed, such as financial results or significant regulatory agreements.
Users can also review other SEC forms associated with VNDA, including exhibits attached to 8-K filings that contain press releases or detailed descriptions of regulatory milestones. For investors analyzing Vanda’s work in sleep-wake disorders, psychiatric conditions, motion sickness, and rare inflammatory skin disease, these filings provide a structured view of the company’s obligations, forward-looking statements, and disclosed risks, while the AI tools on Stock Titan help make the technical language more accessible.
Vanda Pharmaceuticals Inc: The Vanguard Group filed Amendment No. 7 to its Schedule 13G/A reporting that it beneficially owns 0 shares (0%) of Vanda Pharmaceuticals Common Stock following an internal realignment of Vanguard subsidiaries.
The amendment explains certain Vanguard subsidiaries will report separately in reliance on SEC Release No. 34-39538 and states the subsidiaries pursue the same investment strategies previously pursued by The Vanguard Group, Inc. The form is signed by Ashley Grim on 03/27/2026.
Vanda Pharmaceuticals Inc. reported that its President, Chief Executive Officer and Chairman, Dr. Mihael Polymeropoulos, appeared on Fox Business’ Mornings with Maria to discuss pricing and commercial plans for a drug recently approved by the U.S. Food and Drug Administration to prevent vomiting caused by motion.
During the interview, he stated that Vanda is developing a direct-to-consumer channel to provide access to this drug and indicated that the channel is expected to be available in the next couple of months. The company furnished a link to the full televised interview for reference.
Vanda Pharmaceuticals Inc. executive Timothy Williams, its SVP & General Counsel, reported selling 42,434 shares of common stock on March 2, 2026. The shares were sold at a weighted average price of $8.2659 per share solely to satisfy tax obligations arising from the settlement of vested RSUs under the company’s RSU agreements. The transactions occurred in multiple trades at prices ranging from $8.085 to $8.81 per share. After these tax-related sales, Williams directly holds 377,450 shares of Vanda common stock.
Vanda Pharmaceuticals SVP, CFO & Treasurer Kevin Patrick Moran reported an open-market sale of 42,442 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The filing explains these shares were sold to satisfy tax obligations arising from the settlement of vested RSUs under withholding provisions in the RSU agreements. After the sale, Moran directly held 411,380 common shares and indirectly held 635 additional shares through his wife. The sale occurred in multiple transactions at prices ranging from $8.085 to $8.81 per share.
Vanda Pharmaceuticals Inc. senior vice president and chief marketing officer Joakim Wijkstrom executed an open‑market sale of 30,800 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The shares were sold to satisfy tax obligations arising from the settlement of vested restricted stock units under the company’s RSU agreements, rather than as a discretionary share sale. After these transactions, Wijkstrom directly held 333,469 shares of Vanda common stock. The trades were completed in multiple transactions at prices ranging from $8.085 to $8.81 per share.
Vanda Pharmaceuticals President and CEO Mihael Hristos Polymeropoulos reported an open-market sale of 156,235 shares of common stock at a weighted average price of $8.1734 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from the settlement of vested restricted stock units under RSU agreements.
After this transaction, the reporting person directly owned 2,704,496 shares of Vanda Pharmaceuticals common stock.
Vanda Pharmaceuticals Inc. senior vice president of business development Gunther Birznieks reported an open-market sale of 42,431 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The shares were sold to satisfy tax obligations tied to the settlement of vested RSUs. After these transactions, he directly holds 494,197 shares. The sales occurred in multiple trades priced between $8.085 and $8.81 per share.